UURL 財經新聞FINANCE
UURL Finance · Taiwan market + in-depth rewrites · hourly

Taipei Biomed Team Heads to Germany's MEDICA Exhibition

Browser TTS · no download

30-second brief

The Taipei City Department of Economic Development is leading six biomedical companies to the German medical device exhibition opening on November 16, focusing on precision medicine, remote monitoring and smart care, showcasing innovative strength, connecting with overseas buyers to expand business opportunities, and raising the international visibility of Taipei biomedicine.

Team Taipei Gathers Six Companies to Capture International Business Opportunities

MEDICA 2026, the international medical device exhibition in Dusseldorf, Germany, will be held from November 16 to 19 in Dusseldorf, Germany. The Taipei City Department of Economic Development, together with six biomedical companies from the city, will set up the Taipei Pavilion, focusing on precision medicine, remote physiological monitoring, and smart care, showcasing innovative technologies and product applications, actively expanding international cooperation and market opportunities, and enhancing the international visibility of Taipei's biomedical industry.

The Department of Economic Development stated that Taipei City has top medical centers, research institutions and professional talent, combined with sound industrial infrastructure and diverse resources, creating a biomedical industry cluster with international development potential. To help companies expand overseas markets, the city government continues to promote the overseas exhibition program for biomedical companies, having led 67 company-participations in global flagship biomedical exhibitions to date, facilitating nearly 3,000 business matchmaking sessions cumulatively. This time, it is again gathering companies under the Team Taipei city brand to showcase innovation achievements to the international market, promote international exchange and cooperation, and create overseas market opportunities.

Six Companies Showcase Precision Medicine and Smart Monitoring

BioSignal Technology leverages wearable sensing and medical IoT technology to launch a vital signs monitoring system that can collect physiological data such as ECG, heart rate and respiration in real time, and integrates it into a central monitoring platform to improve smart ward and clinical care efficiency. ACT Genomics combines next-generation sequencing and bioinformatics analysis technology to launch a cancer genetic testing solution, helping physicians understand tumor gene mutations and providing a basis for precision medication and personalized treatment decisions. Qiyuan Biotechnology focuses on rapid molecular diagnostic technology, exhibiting rapid genetic testing products covering genetic diseases such as spinal muscular atrophy and Duchenne muscular dystrophy, and launching the E-AST COMBO SYSTEM antibiotic susceptibility testing platform, which uses microfluidic impedance technology to shorten testing time to as fast as four hours, accelerating clinical diagnosis and precision medication decisions.

Guider Technology integrates medical wearable devices, IoT and a cloud health management platform to track users' physiological data in real time, offering diverse applications for medical institutions, long-term care facilities and home care. Dikuo Intelligent Technology combines AI image recognition and differential privacy technology to launch the AipA smart medical system, which identifies scenarios such as falls, bed exits and abnormal movements in real time while protecting personal privacy, improving medical care safety and management efficiency. JUBI International Biomedical, centered on low-temperature plasma technology, has developed JUBI Plasma, combining cold plasma, ultrasound and microbubble engineering to extend professional medical technology to home health and daily care, expanding diverse applications in long-term care and wound repair.

Targeting Precision, Digital and Smart Trends to Expand Overseas Markets

As the global healthcare industry accelerates toward precision, digitalization and intelligence, Taipei biomedical companies, with their innovative R&D and cross-disciplinary integration advantages, have the potential to enter international supply chains and expand overseas markets. The city government hopes that through the MEDICA 2026 international exhibition platform, it can help companies grasp global medical market trends, connect with overseas buyers and strategic partners, and promote Taipei as an important hub for biotech innovation and international cooperation in the Asia-Pacific. For more exhibitor information, follow the BioTaipei thematic website.

FAQ

When and where will MEDICA 2026 be held? What are the features of the Taipei Pavilion?

The exhibition will be held from November 16 to 19 in Dusseldorf, Germany. The Taipei Pavilion is led by the Department of Economic Development with six companies participating under the Team Taipei brand, focusing on precision medicine, remote physiological monitoring and smart care.

What technologies are the six participating Taipei biomedical companies showcasing?

Covering BioSignal Technology vital signs monitoring, ACT Genomics cancer genetic testing, Qiyuan Biotechnology rapid genetic testing and drug susceptibility testing platform, Guider Technology cloud health management, Dikuo Intelligence AipA system, and JUBI low-temperature plasma technology.

How does Taipei City help biomedical companies expand overseas markets?

The city government promotes the overseas exhibition program, having led 67 company-participations in flagship exhibitions to date, facilitating nearly 3,000 business matchmaking sessions cumulatively, aiming to connect with buyers and partners through exhibitions and enter international supply chains.